Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Adempas Approved in EU for Life-Threatening Hypertension

March 31, 2014 10:49 am | News | Comments

Bayer announced that Adempas (riociguat) has been approved by the European Commission for the treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Read more...             

TOPICS:

Jazz Rolls Out Defitelio for sVOD in Europe

March 31, 2014 10:41 am | News | Comments

Jazz Pharmaceuticals and Gentium S.p.A. announced the commencement of the European commercial launch of Defitelio (defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients undergoing HSCT therapy. Read more...

TOPICS:

AstraZeneca, MRC Enter Drug Discovery Collaboration

March 31, 2014 10:21 am | News | Comments

AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better understanding the mechanisms of human disease and potential treatment options. Read more...       

TOPICS:
Advertisement

Novartis Ends Heart Drug Trial on Effectiveness

March 31, 2014 10:14 am | News | Comments

Novartis said it's cutting off late-stage research into a potential chronic heart failure treatment because the drug has proven so effective, sending shares to an all-time high when markets opened Monday. Read more...         

TOPICS:

Prana Alzheimer’s Drug Misses Primary Endpoint in Phase 2

March 31, 2014 10:10 am | News | Comments

Prana Biotechnology announced that its lead Alzheimer's drug candidate, PBT2, did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients. Read more...

TOPICS:

FDA OKs Biogen Hemophilia Treatment

March 31, 2014 9:58 am | News | Comments

The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes. Read more...               

TOPICS:

Gene Therapy May Thwart Effects of MS

March 28, 2014 3:25 pm | News | Comments

Researchers have received a grant from the National Multiple Sclerosis Society to test a gene therapy technique in mice that aims to help the body not treat itself like a foreign invader. Read more...               

TOPICS:

Scientists Awarded $2.3M to Study Dengue Fever, Related Viruses

March 28, 2014 3:18 pm | News | Comments

A group of scientists has been awarded $2.3 million to study a category of viruses that cause dengue fever, West Nile, yellow fever and other diseases spread by mosquitoes and ticks. Read more...                 

TOPICS:
Advertisement

PDF Providing Grants to Speed New Parkinson's Treatments

March 28, 2014 3:05 pm | News | Comments

The Parkinson's Disease Foundation (PDF) is pleased to announce $20,000 in grant funding to support patient-centered research at four leading Parkinson's disease research institutions. Read more...                

TOPICS:

Women with BRCA1 Mutation Could Use Drugs to Cut Cancer Risk

March 28, 2014 2:46 pm | News | Comments

Cancer researchers have discovered that women affected with BRCA1 mutation could use drugs, which are already available, to reduce their risk of developing the disease, rather than undergo irreversible surgery. Read more...       

TOPICS:

Idera Posts Positive Data in Phase 2 Psoriasis Trial

March 28, 2014 2:27 pm | News | Comments

Idera Pharmaceuticals Inc. announced positive top-line data from its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Read more...            

TOPICS:

Takeda, Dainippon Sumitomo Get Schizophrenia Drug Approval Europe

March 28, 2014 11:14 am | News | Comments

Dainippon Sumitomo Pharma and Takeda Pharmaceutical jointly announced that the European Commission has granted Marketing Authorization for once-daily oral Latuda (lurasidone) for the treatment of schizophrenia in adults. Read more...      

TOPICS:

Europe OKs New Formula of Roche Cancer Drug

March 28, 2014 11:10 am | News | Comments

Roche announced that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Read more...         

TOPICS:

EMA Validates Gilead’s App for Hep C Combo Therapy

March 28, 2014 11:06 am | News | Comments

Gilead Sciences Inc. announced that the company’s Marketing Authorization Application for a fixed-dose combination of ledipasvir and sofosbuvir for the treatment of chronic hepatitis C virus, genotype 1 infection, has been fully validated and is now under assessment by the EMA. Read more...

TOPICS:

EC Approves GSK's Once-Weekly Diabetes Treatment

March 28, 2014 10:58 am | News | Comments

GlaxoSmithKline plc announced that the European Commission has granted marketing authorization for its once-weekly diabetes treatment, Eperzan (albiglutide). Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading